BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Reputational Risks · 31 Aug 2026
Paradigm Peptides Owner Sentenced to 70 Months: What the First Major Criminal Conviction in the Research-Use-Only Market Means for Research Procurement
A US federal judge sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison on 30 July 2026, after he admitted importing unapproved drugs from China and India and misrepresenting them as domestically manufactured, FDA-registered products. The case is widely regarded as the first significant criminal prosecution in the largely unregulated "research-use only" peptide marketplace, and it carries direct implications for research procurement officers assessing supplier risk.
Read briefing →
Research Pipeline
MOTS-c: The Mitochondrial-Encoded Peptide With a Favourable PCAC Vote, Emerging Human Trial Data, and a Long Road to Compounding Approval
MOTS-c received a favourable 7-5 PCAC recommendation on 23 July 2026 for inclusion on the FDA's 503A Bulks List, yet formal rulemaking remains ahead. This briefing examines MOTS-c's mitochondrial mechanism, the state of its preclinical and early clinical evidence, and what the PCAC outcome means for research procurement in the UK and US.
30 Aug 2026
Research Pipeline
Selank: The Tuftsin-Derived Heptapeptide With Russian Regulatory Approval, Modest Western Evidence, and a Changed FDA Compounding Status in 2026
Selank is a synthetic heptapeptide developed in Russia that holds domestic regulatory approval as a prescription anxiolytic and has the most substantial human clinical dataset of any nootropic-class peptide in the Western research conversation. This briefing covers its mechanism, the state of the evidence, its 2026 FDA compounding reclassification, and what that means for UK research-procurement teams.
29 Aug 2026
Research Pipeline
KPV: The Alpha-MSH Tripeptide With an 8-6 PCAC Vote, Two Decades of Preclinical Data, and No Human Clinical Trials
KPV (lysine-proline-valine) is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone with preclinical anti-inflammatory evidence spanning gut, skin, and innate immunity. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend it for the 503A Bulks List — but no human clinical trials have been completed, FDA staff recommended against inclusion, and formal rulemaking has yet to begin.
28 Aug 2026
Pharma & GLP-1
Foundayo (Orforglipron) Lands in UK Pharmacies: What the MHRA Approval and Private Launch Mean for the GLP-1 Landscape
Eli Lilly's oral GLP-1 receptor agonist orforglipron (Foundayo) launched in UK private pharmacies on 24 August 2026, three weeks after the MHRA became the first European regulator to authorise it. As a non-peptide small molecule — not a peptide drug — it represents a structurally distinct route to GLP-1 receptor activation with supply-chain implications that differ from conventional peptide-based agents.
27 Aug 2026
Research Pipeline
TB-500: The Thymosin Beta-4 Fragment With an 8-6 PCAC Vote, Decades of Preclinical Data, and No Human Efficacy Trials
TB-500, the synthetic 17-amino acid fragment of thymosin beta-4, received a favourable 8-6 advisory vote from the FDA's Pharmacy Compounding Advisory Committee on 23 July 2026 — despite agency staff recommending against listing it. No controlled human efficacy trial has yet administered TB-500 directly, making the evidence gap between preclinical promise and regulatory legitimacy unusually pronounced.
26 Aug 2026
Regulatory & Policy
FDA Publishes 17 Revised Draft Product-Specific Guidances for Generic Peptides: What the New Testing Standards Mean
On 28 July 2026, the FDA released revised draft product-specific guidances for 17 injectable peptide products, including semaglutide, tirzepatide, liraglutide, and teriparatide, setting updated standards for bioequivalence, impurity thresholds, and biological activity assessment. The comment window closes 28 September 2026, making this an active regulatory moment for developers and procurement teams alike.
25 Aug 2026
Research Pipeline
Epitalon: The Pineal Tetrapeptide With a PCAC Vote, Four Decades of Russian Research, and No Western Clinical Trials
Epitalon, a synthetic tetrapeptide derived from a pineal-gland extract, received a favourable PCAC recommendation on 24 July 2026 — cleared 7-5 against FDA staff advice. Its evidence base spans four decades of Russian research, compelling in vitro and animal data, and a near-complete absence of independent Western clinical trials. This profile examines the mechanism, the literature, and what the regulatory development means for UK research procurement.
24 Aug 2026
Research Pipeline
CJC-1295 and Ipamorelin: Mechanism, Evidence Base, and Regulatory Position in 2026
CJC-1295 and ipamorelin are the two most widely researched growth hormone secretagogue peptides in research procurement. Both remain on the FDA's Category 2 list pending further review, carry a mechanistically coherent combined-use rationale, and yet lack the clinical trial depth that would support approved compounding. This briefing covers their pharmacology, the state of the evidence, and what their regulatory position means for UK research laboratories.
23 Aug 2026
Pharma & GLP-1
Samsung Biologics' $1.8 Billion Bid for PolyPeptide: What the Largest Peptide CDMO Acquisition of 2026 Means for the Supply Chain
Samsung Biologics has launched a CHF 1.46 billion all-cash tender offer to acquire Swiss peptide CDMO PolyPeptide Group, with the formal prospectus due by end of August 2026. The deal — the largest peptide manufacturing acquisition of the year — reflects structural demand for GLP-1 API capacity and signals a further consolidation of the CDMO landscape that research-procurement teams should factor into sourcing strategy.
22 Aug 2026
Regulatory & Policy
FDA's Proposed 503B Exclusion of Compounded GLP-1s: What the NPRM Means, Where the Rule Stands, and What Research Suppliers Need to Know
The FDA's April 2026 notice of proposed rulemaking would permanently bar 503B outsourcing facilities from bulk-compounding semaglutide, tirzepatide, and liraglutide. The public comment period has closed and a final rule is pending — a development that stands in sharp contrast to the July PCAC votes favouring expanded access to non-GLP-1 peptides.
21 Aug 2026
Research Pipeline
BPC-157 After the PCAC Vote: What the 8-6 Decision Means, Where the Evidence Stands, and What Comes Next
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on 23 July 2026 to recommend BPC-157 for the 503A Bulk Drug Substances List — overruling its own career scientists. The vote is non-binding, formal rulemaking will take at least 12 months, and the human evidence base remains extremely thin. This briefing sets out what the decision means in practice for research procurement teams.
20 Aug 2026